Fri, Jul 25, 2014, 11:07 AM EDT - U.S. Markets close in 4 hrs 53 mins


% | $
Click the to save as a favorite.

Momenta Pharmaceuticals Inc. Message Board

  • y3maxx y3maxx Nov 30, 2011 12:18 PM Flag


    Since no logical reason can be found in Dew's RMF, why MNTA trades as weakly as it does, I suggest Longs consider...

    ...that it is in NVS/Sandoz's interest to delay Sandoz/MNTA's Mcopax FDA approval as long as is possible, because at some point Sandoz/NVS will buy out MNTA for as cheap as possible.

    ...Only $$$ Billions are at stake.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You're making a lot of assumptions that are faulty....

      1. You're assuming that NVS/Sandoz has influence and/or control over the timing and the approval of M-copax. The ANDA has already been filed w/ the FDA, and now FDA has sole discretion if and when to approve. If NVS/Sandoz wanted to delay the approval of M-copax, they wouldn't have filed the ANDA to begin with (or at least would have delayed it when they could exert influence).

      2. From a MNTA buyout perspective, it could be possible that NVS/Sandoz may want to delay M-copax approval. But from a cash flow perspective, they'll want M-copax approval AS SOON AS POSSIBLE.

      3. If billions are at stake, MNTA would receive a takeover offer TODAY. MNTA is trading at less than $400M ex cash, which is nothing compared to the revenues and mkt cap of the large biotech & pharmas. Are u saying that potential suitors are waiting until MNTA's mkt cap falls closer to its cash value? I highly doubt that.

10.81-0.18(-1.62%)11:03 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.